Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
&&$LOCK|Z#LOCK|b$$&SZ

Merck Earnings: Shares Look Fairly Valued Approaching Key Pipeline Data

Merck reported 2025 results, including 1% revenue growth and 17% non-GAAP EPS growth. For 2026, management has guided to a revenue range of roughly 1-3% growth and non-GAAP EPS of $5.00-$5.15 (lower due to charges related to the Cidara acquisition).

Sponsor Center